Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of HBM9161 in generalized myasthenia gravis
ChiCTR2000033560Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of batoclimab in myasthenia gravis (MG) (3 arms), sponsored by Huashan Hospital. Primary endpoint: Change in Myasthenia Gravis Activities of Daily Living score. Planned start May 2020; status: not yet recruiting.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2000033560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033560.